<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>Stephen Simpson's Comments</title>
    <description>Stephen Simpson's Comments RSS Syndication from SeekingAlpha.com</description>
    <link>http://seekingalpha.com/user/542417/comments</link>
    <item>
      <title>LipoScience Gives Its Shareholders Chest Pains</title>
      <link>http://seekingalpha.com/article/1431361/comments?source=feed#comment-18893341</link>
      <guid isPermaLink="false">18893341</guid>
      <content>
        <![CDATA[Not exactly. I think they will eventually reach a &quot;steady state&quot;. <br/><br/>I expect the majority of their business going forward will be through the big labs - it just makes more sense for the hospitals/clinics to outsource their lab functions as opposed to buying the equipment, hiring the techs, etc. <br/><br/>I think the size of the business today is small enough that this conversion issue is a big deal, but it won't (shouldn't?) be an enduring issue.]]>
      </content>
      <pubDate>Thu, 16 May 2013 09:34:29 -0400</pubDate>
      <description>
        <![CDATA[Not exactly. I think they will eventually reach a &quot;steady state&quot;. <br/><br/>I expect the majority of their business going forward will be through the big labs - it just makes more sense for the hospitals/clinics to outsource their lab functions as opposed to buying the equipment, hiring the techs, etc. <br/><br/>I think the size of the business today is small enough that this conversion issue is a big deal, but it won't (shouldn't?) be an enduring issue.]]>
      </description>
    </item>
    <item>
      <title>Can Uroplasty Drive Adoption Of Its Better Mousetrap?</title>
      <link>http://seekingalpha.com/article/454691/comments?source=feed#comment-18665931</link>
      <guid isPermaLink="false">18665931</guid>
      <content>
        <![CDATA[Thanks for pointing that out Eli. <br/>It helps, but one of the big challenges is getting patient compliance ... and unfortunately, most patients don't follow data. ]]>
      </content>
      <pubDate>Fri, 10 May 2013 08:00:53 -0400</pubDate>
      <description>
        <![CDATA[Thanks for pointing that out Eli. <br/>It helps, but one of the big challenges is getting patient compliance ... and unfortunately, most patients don't follow data. ]]>
      </description>
    </item>
    <item>
      <title>Erickson Air-Crane Has Scarcity, But Value Is Difficult To Judge</title>
      <link>http://seekingalpha.com/article/1382021/comments?source=feed#comment-18313191</link>
      <guid isPermaLink="false">18313191</guid>
      <content>
        <![CDATA[Fair enough. No apologies needed. <br/><br/>In case I wasn't explicit enough before, I'll say that I think mgmt's synergy goals for the first 18 months are too ambitious. I model 25% EBITDA margin for 2014.]]>
      </content>
      <pubDate>Wed, 01 May 2013 10:50:19 -0400</pubDate>
      <description>
        <![CDATA[Fair enough. No apologies needed. <br/><br/>In case I wasn't explicit enough before, I'll say that I think mgmt's synergy goals for the first 18 months are too ambitious. I model 25% EBITDA margin for 2014.]]>
      </description>
    </item>
    <item>
      <title>Erickson Air-Crane Has Scarcity, But Value Is Difficult To Judge</title>
      <link>http://seekingalpha.com/article/1382021/comments?source=feed#comment-18312321</link>
      <guid isPermaLink="false">18312321</guid>
      <content>
        <![CDATA[And I'll say this again, since nobody seems to be acknowledging that I've said this before - I think EHI is on balance a good deal. I just think that the EBITDA expectations are too high in the near-term. <br/><br/>Moreover, I said that my FV estimate for *today* based on 2014 EBITDA is $26 - higher, I believe, than the current sell-side avg price target. <br/><br/>I honestly don't know what you're all so riled up about. ]]>
      </content>
      <pubDate>Wed, 01 May 2013 10:30:46 -0400</pubDate>
      <description>
        <![CDATA[And I'll say this again, since nobody seems to be acknowledging that I've said this before - I think EHI is on balance a good deal. I just think that the EBITDA expectations are too high in the near-term. <br/><br/>Moreover, I said that my FV estimate for *today* based on 2014 EBITDA is $26 - higher, I believe, than the current sell-side avg price target. <br/><br/>I honestly don't know what you're all so riled up about. ]]>
      </description>
    </item>
    <item>
      <title>Erickson Air-Crane Has Scarcity, But Value Is Difficult To Judge</title>
      <link>http://seekingalpha.com/article/1382021/comments?source=feed#comment-18311511</link>
      <guid isPermaLink="false">18311511</guid>
      <content>
        <![CDATA[Companies routinely &quot;drop hundreds of millions on buying a business&quot; that destroys shareholder value, and sometimes almost immediately. <br/><br/>Go back five years and look at the number of homebuilders and/or building supply companies that used debt to make multi-hundred million dollar acquisitions at/near the peak.<br/><br/>Look at the number of oil/gas and mineral companies that spend millions/billions on acquisitions at the peak of the cycle. <br/><br/>Look at CAT's recent purchase of that Chinese mining company and the subsequent writedown of 80%+ of the purchase price (fraud-related in this specific case). You don't think CAT management thought that they &quot;fully vetted&quot; the deal? And we're talking about CAT, a Dow stock, and not a $300M helicopter services company.<br/><br/>Corporate executives routinely make bad deals and then try to sell the Street on the notion that they just made a great deal. That's been going on for decades. <br/><br/>Look, if you think EAC is great, go buy it. I really don't care. This is my analysis and you're free to accept it or reject it as you like. I will continue to maintain that blindly accepting whatever management says is NOT analysis, but if that's what you want to go with, it doesn't cost me a dime. Just don't complain that you weren't warned if/when it blows up in your face.]]>
      </content>
      <pubDate>Wed, 01 May 2013 10:08:05 -0400</pubDate>
      <description>
        <![CDATA[Companies routinely &quot;drop hundreds of millions on buying a business&quot; that destroys shareholder value, and sometimes almost immediately. <br/><br/>Go back five years and look at the number of homebuilders and/or building supply companies that used debt to make multi-hundred million dollar acquisitions at/near the peak.<br/><br/>Look at the number of oil/gas and mineral companies that spend millions/billions on acquisitions at the peak of the cycle. <br/><br/>Look at CAT's recent purchase of that Chinese mining company and the subsequent writedown of 80%+ of the purchase price (fraud-related in this specific case). You don't think CAT management thought that they &quot;fully vetted&quot; the deal? And we're talking about CAT, a Dow stock, and not a $300M helicopter services company.<br/><br/>Corporate executives routinely make bad deals and then try to sell the Street on the notion that they just made a great deal. That's been going on for decades. <br/><br/>Look, if you think EAC is great, go buy it. I really don't care. This is my analysis and you're free to accept it or reject it as you like. I will continue to maintain that blindly accepting whatever management says is NOT analysis, but if that's what you want to go with, it doesn't cost me a dime. Just don't complain that you weren't warned if/when it blows up in your face.]]>
      </description>
    </item>
    <item>
      <title>Erickson Air-Crane Has Scarcity, But Value Is Difficult To Judge</title>
      <link>http://seekingalpha.com/article/1382021/comments?source=feed#comment-18297381</link>
      <guid isPermaLink="false">18297381</guid>
      <content>
        <![CDATA[And just as a follow-up ... I realize that much of EHI's Afghan business is medevac, but I still believe the volume is going to decline significantly over the next two years.]]>
      </content>
      <pubDate>Tue, 30 Apr 2013 22:31:09 -0400</pubDate>
      <description>
        <![CDATA[And just as a follow-up ... I realize that much of EHI's Afghan business is medevac, but I still believe the volume is going to decline significantly over the next two years.]]>
      </description>
    </item>
    <item>
      <title>Erickson Air-Crane Has Scarcity, But Value Is Difficult To Judge</title>
      <link>http://seekingalpha.com/article/1382021/comments?source=feed#comment-18296811</link>
      <guid isPermaLink="false">18296811</guid>
      <content>
        <![CDATA[indytom01 - Afghanistan is supposedly around 60% of EHI's revenue, and the U.S. pullout is supposed to be complete by 2014. That a huge piece of business to replace, particularly as operations like these encounter large dis-economies of scale as the utilization rates decline. <br/><br/>So, you have the sequester, the probable future cuts in defense spending, particularly in manpower and mobilization, and the Afghan wind-down. Moreover, in past periods of DoD spending cuts, eliminating outsiders has been a common move. I believe that is going to hammer EHI's profitability, and I believe EAC is going to have a difficult time reassigning those aircraft to firefighting, construction, or timber operations at similar levels of net profitability right away. <br/><br/>Long term, it's a not a problem (I think they're buying good assets at a reasonable price). I just think the expectations for 2013/2014 EBITDA are too high. Moreover, the free cash flow outlook (net of debt) just isn't that strong.]]>
      </content>
      <pubDate>Tue, 30 Apr 2013 22:07:50 -0400</pubDate>
      <description>
        <![CDATA[indytom01 - Afghanistan is supposedly around 60% of EHI's revenue, and the U.S. pullout is supposed to be complete by 2014. That a huge piece of business to replace, particularly as operations like these encounter large dis-economies of scale as the utilization rates decline. <br/><br/>So, you have the sequester, the probable future cuts in defense spending, particularly in manpower and mobilization, and the Afghan wind-down. Moreover, in past periods of DoD spending cuts, eliminating outsiders has been a common move. I believe that is going to hammer EHI's profitability, and I believe EAC is going to have a difficult time reassigning those aircraft to firefighting, construction, or timber operations at similar levels of net profitability right away. <br/><br/>Long term, it's a not a problem (I think they're buying good assets at a reasonable price). I just think the expectations for 2013/2014 EBITDA are too high. Moreover, the free cash flow outlook (net of debt) just isn't that strong.]]>
      </description>
    </item>
    <item>
      <title>No News Becoming Bad News For Lexicon Pharmaceuticals</title>
      <link>http://seekingalpha.com/article/1382091/comments?source=feed#comment-18287851</link>
      <guid isPermaLink="false">18287851</guid>
      <content>
        <![CDATA[If I remember right, AMLN got $100M from LLY upfront, quite a bit more in milestones, and they split costs 50/50 in the US after the first $100M. For that AMLN got additional milestones and a 50/50 operating profit split. That was for a first-in-class drug. <br/><br/>Isis got $45M from JNJ for a two-drug partnership back in 2007. Again, that would have been a first-in-class drug.<br/><br/>Long before that, NKTR got a smaller upfront from Pfizer for Exubera, but that was a weird deal all around. <br/><br/>Normally I'd think $30M to $45M upfront, with most of the costs paid for by the partner would feel about right. ]]>
      </content>
      <pubDate>Tue, 30 Apr 2013 17:09:27 -0400</pubDate>
      <description>
        <![CDATA[If I remember right, AMLN got $100M from LLY upfront, quite a bit more in milestones, and they split costs 50/50 in the US after the first $100M. For that AMLN got additional milestones and a 50/50 operating profit split. That was for a first-in-class drug. <br/><br/>Isis got $45M from JNJ for a two-drug partnership back in 2007. Again, that would have been a first-in-class drug.<br/><br/>Long before that, NKTR got a smaller upfront from Pfizer for Exubera, but that was a weird deal all around. <br/><br/>Normally I'd think $30M to $45M upfront, with most of the costs paid for by the partner would feel about right. ]]>
      </description>
    </item>
    <item>
      <title>No News Becoming Bad News For Lexicon Pharmaceuticals</title>
      <link>http://seekingalpha.com/article/1382091/comments?source=feed#comment-18286441</link>
      <guid isPermaLink="false">18286441</guid>
      <content>
        <![CDATA[I want to say that LXRX mgmt made it pretty clear at least a year ago that there were looking to partner this one, and didn't intend to go into P3 solo. Now, I'm not sure of that time estimate (don't have my notes in front of me), but that's what's in my memory...<br/><br/>I was referring more specifically to what sell-side analysts were doing insofar as setting a target date, seeing it go by, and then setting a new one. I don't think mgmt has said more than &quot;before we start P3&quot; as the target date.]]>
      </content>
      <pubDate>Tue, 30 Apr 2013 16:42:39 -0400</pubDate>
      <description>
        <![CDATA[I want to say that LXRX mgmt made it pretty clear at least a year ago that there were looking to partner this one, and didn't intend to go into P3 solo. Now, I'm not sure of that time estimate (don't have my notes in front of me), but that's what's in my memory...<br/><br/>I was referring more specifically to what sell-side analysts were doing insofar as setting a target date, seeing it go by, and then setting a new one. I don't think mgmt has said more than &quot;before we start P3&quot; as the target date.]]>
      </description>
    </item>
    <item>
      <title>No News Becoming Bad News For Lexicon Pharmaceuticals</title>
      <link>http://seekingalpha.com/article/1382091/comments?source=feed#comment-18285961</link>
      <guid isPermaLink="false">18285961</guid>
      <content>
        <![CDATA[IALF, that's a reasonable hypothesis. The problem is, analysts have been projecting a partnership for a while now, seeing the estimated deadline go by, and then saying &quot;well, partners are probably waiting for this next piece of data&quot;. <br/><br/>So, I'm not mocking you at all, nor arguing with you. Rather, just offering up that others have said that before about other incremental datapoints. ]]>
      </content>
      <pubDate>Tue, 30 Apr 2013 16:31:32 -0400</pubDate>
      <description>
        <![CDATA[IALF, that's a reasonable hypothesis. The problem is, analysts have been projecting a partnership for a while now, seeing the estimated deadline go by, and then saying &quot;well, partners are probably waiting for this next piece of data&quot;. <br/><br/>So, I'm not mocking you at all, nor arguing with you. Rather, just offering up that others have said that before about other incremental datapoints. ]]>
      </description>
    </item>
    <item>
      <title>Erickson Air-Crane Has Scarcity, But Value Is Difficult To Judge</title>
      <link>http://seekingalpha.com/article/1382021/comments?source=feed#comment-18285841</link>
      <guid isPermaLink="false">18285841</guid>
      <content>
        <![CDATA[Right, because company guidance is never wrong. Yep, companies never miss or surprise. Nope, never...]]>
      </content>
      <pubDate>Tue, 30 Apr 2013 16:29:03 -0400</pubDate>
      <description>
        <![CDATA[Right, because company guidance is never wrong. Yep, companies never miss or surprise. Nope, never...]]>
      </description>
    </item>
    <item>
      <title>No News Becoming Bad News For Lexicon Pharmaceuticals</title>
      <link>http://seekingalpha.com/article/1382091/comments?source=feed#comment-18285391</link>
      <guid isPermaLink="false">18285391</guid>
      <content>
        <![CDATA[Interesting thought on shopping the company. Don't necessarily disagree, but that could be a challenging sale. <br/><br/>Then again, who knows? Maybe that explains why the P3 partnership announcement is so long in coming.]]>
      </content>
      <pubDate>Tue, 30 Apr 2013 16:18:56 -0400</pubDate>
      <description>
        <![CDATA[Interesting thought on shopping the company. Don't necessarily disagree, but that could be a challenging sale. <br/><br/>Then again, who knows? Maybe that explains why the P3 partnership announcement is so long in coming.]]>
      </description>
    </item>
    <item>
      <title>Erickson Air-Crane Has Scarcity, But Value Is Difficult To Judge</title>
      <link>http://seekingalpha.com/article/1382021/comments?source=feed#comment-18285331</link>
      <guid isPermaLink="false">18285331</guid>
      <content>
        <![CDATA[Analysis means doing something more than just regurgitating the company's numbers. Moreover, if you think a business that gets such a large piece of its revenue and EBITDA from U.S. DoD activity (particularly in Afghanistan) isn't going to see some significant changes in 2013 and 2014, then I really don't know what to say to you. ]]>
      </content>
      <pubDate>Tue, 30 Apr 2013 16:17:42 -0400</pubDate>
      <description>
        <![CDATA[Analysis means doing something more than just regurgitating the company's numbers. Moreover, if you think a business that gets such a large piece of its revenue and EBITDA from U.S. DoD activity (particularly in Afghanistan) isn't going to see some significant changes in 2013 and 2014, then I really don't know what to say to you. ]]>
      </description>
    </item>
    <item>
      <title>MJNA:  Seeking Alpha Writers Litigation Is Misguided</title>
      <link>http://seekingalpha.com/instablog/6880-alan-brochstein/1809481-mjna-seeking-alpha-writers-litigation-is-misguided?source=feed#comment-18271901</link>
      <guid isPermaLink="false">18271901</guid>
      <content>
        <![CDATA[Alan, <br/><br/>I love it when lousy companies start throwing around allegations of misrepresentation, defamation, and so on. While it plays well to their crowd (credulous retail investors), I think they'd find the discovery process of an actual lawsuit to be quite adverse to their own interests. ]]>
      </content>
      <pubDate>Tue, 30 Apr 2013 11:36:13 -0400</pubDate>
      <description>
        <![CDATA[Alan, <br/><br/>I love it when lousy companies start throwing around allegations of misrepresentation, defamation, and so on. While it plays well to their crowd (credulous retail investors), I think they'd find the discovery process of an actual lawsuit to be quite adverse to their own interests. ]]>
      </description>
    </item>
    <item>
      <title>The Haze Lifts: 96% Of Medical Marijuana Inc. Q4 Sales From Questionable Transaction</title>
      <link>http://seekingalpha.com/article/1369511/comments?source=feed#comment-18092461</link>
      <guid isPermaLink="false">18092461</guid>
      <content>
        <![CDATA[Actually, Ashraf, more like a small army of fresh-out-of-school lawyers that really want to work in the big leagues and pay off their school loans. ]]>
      </content>
      <pubDate>Thu, 25 Apr 2013 14:31:20 -0400</pubDate>
      <description>
        <![CDATA[Actually, Ashraf, more like a small army of fresh-out-of-school lawyers that really want to work in the big leagues and pay off their school loans. ]]>
      </description>
    </item>
    <item>
      <title>Consumer Staples: Like Apple At $700 Or Gold At $1900</title>
      <link>http://seekingalpha.com/article/1339491/comments?source=feed#comment-17605711</link>
      <guid isPermaLink="false">17605711</guid>
      <content>
        <![CDATA[Valuations already are baking in considerable improvements in ROE and growth. It's not a cheap sector apart from a few high-quality names (JPM/WFC/USB, maybe BBT).]]>
      </content>
      <pubDate>Sun, 14 Apr 2013 13:58:51 -0400</pubDate>
      <description>
        <![CDATA[Valuations already are baking in considerable improvements in ROE and growth. It's not a cheap sector apart from a few high-quality names (JPM/WFC/USB, maybe BBT).]]>
      </description>
    </item>
    <item>
      <title>Consumer Staples: Like Apple At $700 Or Gold At $1900</title>
      <link>http://seekingalpha.com/article/1339491/comments?source=feed#comment-17597901</link>
      <guid isPermaLink="false">17597901</guid>
      <content>
        <![CDATA[Trouble with financials is that the stocks that look good on price are going nowhere in terms of PPNR growth, while those that are showing some growth are pretty fully valued. ]]>
      </content>
      <pubDate>Sun, 14 Apr 2013 09:33:33 -0400</pubDate>
      <description>
        <![CDATA[Trouble with financials is that the stocks that look good on price are going nowhere in terms of PPNR growth, while those that are showing some growth are pretty fully valued. ]]>
      </description>
    </item>
    <item>
      <title>Consumer Staples: Like Apple At $700 Or Gold At $1900</title>
      <link>http://seekingalpha.com/article/1339491/comments?source=feed#comment-17597361</link>
      <guid isPermaLink="false">17597361</guid>
      <content>
        <![CDATA[Well done, Alan. I'm definitely having to think long and hard about riding my consumer stocks much higher from here. Looks like more bargains are cropping up in tech and materials, but when you see reports like ORCL, FFIV, and FTNT, it's hard to have confidence that tech isn't getting &quot;cheap for a reason&quot;. ]]>
      </content>
      <pubDate>Sun, 14 Apr 2013 09:15:48 -0400</pubDate>
      <description>
        <![CDATA[Well done, Alan. I'm definitely having to think long and hard about riding my consumer stocks much higher from here. Looks like more bargains are cropping up in tech and materials, but when you see reports like ORCL, FFIV, and FTNT, it's hard to have confidence that tech isn't getting &quot;cheap for a reason&quot;. ]]>
      </description>
    </item>
    <item>
      <title>2 Volatile Tech Stocks To Consider On This Drop</title>
      <link>http://seekingalpha.com/article/1319921/comments?source=feed#comment-17210851</link>
      <guid isPermaLink="false">17210851</guid>
      <content>
        <![CDATA[&quot; Usually share price reflects how well the company is managed&quot;<br/><br/>If you really believe that, what's the point of investing in individual stocks? The whole point of active investment is the notion that stock prices can deviate (sometimes very significantly) from the intrinsic value of the company. ]]>
      </content>
      <pubDate>Thu, 04 Apr 2013 10:22:50 -0400</pubDate>
      <description>
        <![CDATA[&quot; Usually share price reflects how well the company is managed&quot;<br/><br/>If you really believe that, what's the point of investing in individual stocks? The whole point of active investment is the notion that stock prices can deviate (sometimes very significantly) from the intrinsic value of the company. ]]>
      </description>
    </item>
    <item>
      <title>2 Volatile Tech Stocks To Consider On This Drop</title>
      <link>http://seekingalpha.com/article/1319921/comments?source=feed#comment-17202321</link>
      <guid isPermaLink="false">17202321</guid>
      <content>
        <![CDATA[Thoughts on ATML down here? Not sure it meets the &quot;intact growth story&quot; criteria, though the microcontroller business could recover in 2013...]]>
      </content>
      <pubDate>Thu, 04 Apr 2013 06:33:04 -0400</pubDate>
      <description>
        <![CDATA[Thoughts on ATML down here? Not sure it meets the &quot;intact growth story&quot; criteria, though the microcontroller business could recover in 2013...]]>
      </description>
    </item>
    <item>
      <title>Looking For Laggards Not Losers</title>
      <link>http://seekingalpha.com/article/1312611/comments?source=feed#comment-17116801</link>
      <guid isPermaLink="false">17116801</guid>
      <content>
        <![CDATA[Sorry Alan, didn't mean to seem like I was grilling you on this point. I was just curious if you had anyone in mind when you mentioned M&amp;A as an angle for VAR. ]]>
      </content>
      <pubDate>Tue, 02 Apr 2013 12:26:59 -0400</pubDate>
      <description>
        <![CDATA[Sorry Alan, didn't mean to seem like I was grilling you on this point. I was just curious if you had anyone in mind when you mentioned M&amp;A as an angle for VAR. ]]>
      </description>
    </item>
    <item>
      <title>Looking For Laggards Not Losers</title>
      <link>http://seekingalpha.com/article/1312611/comments?source=feed#comment-17115861</link>
      <guid isPermaLink="false">17115861</guid>
      <content>
        <![CDATA[You know that Siemens bailed out on its rad-onc business about 18mo ago, right? I'm not sure they'd want to pay the premium to get back into the business by buying VAR (nor face their shareholders if they did...). ]]>
      </content>
      <pubDate>Tue, 02 Apr 2013 12:09:37 -0400</pubDate>
      <description>
        <![CDATA[You know that Siemens bailed out on its rad-onc business about 18mo ago, right? I'm not sure they'd want to pay the premium to get back into the business by buying VAR (nor face their shareholders if they did...). ]]>
      </description>
    </item>
    <item>
      <title>Looking For Laggards Not Losers</title>
      <link>http://seekingalpha.com/article/1312611/comments?source=feed#comment-17115401</link>
      <guid isPermaLink="false">17115401</guid>
      <content>
        <![CDATA[Who do you think buys Varian? <br/>GE's about the only co I could see doing it, and I don't really think they're all that interested. ]]>
      </content>
      <pubDate>Tue, 02 Apr 2013 12:00:42 -0400</pubDate>
      <description>
        <![CDATA[Who do you think buys Varian? <br/>GE's about the only co I could see doing it, and I don't really think they're all that interested. ]]>
      </description>
    </item>
    <item>
      <title>Endologix Shows How Growth-Hungry Med-Tech Investors Are</title>
      <link>http://seekingalpha.com/article/1308031/comments?source=feed#comment-17088281</link>
      <guid isPermaLink="false">17088281</guid>
      <content>
        <![CDATA[Thank you for pointing out the &quot;vein&quot; mistakes. Stupid typos on my part. ]]>
      </content>
      <pubDate>Mon, 01 Apr 2013 17:19:39 -0400</pubDate>
      <description>
        <![CDATA[Thank you for pointing out the &quot;vein&quot; mistakes. Stupid typos on my part. ]]>
      </description>
    </item>
    <item>
      <title>Endologix Shows How Growth-Hungry Med-Tech Investors Are</title>
      <link>http://seekingalpha.com/article/1308031/comments?source=feed#comment-17009881</link>
      <guid isPermaLink="false">17009881</guid>
      <content>
        <![CDATA[Agreed, Paul. With only a scant few exceptions, anything that's cheap is &quot;cheap for a reason&quot;. ]]>
      </content>
      <pubDate>Sat, 30 Mar 2013 09:39:46 -0400</pubDate>
      <description>
        <![CDATA[Agreed, Paul. With only a scant few exceptions, anything that's cheap is &quot;cheap for a reason&quot;. ]]>
      </description>
    </item>
    <item>
      <title>For Sandy Spring Bancorp, It Looks Like Buy Or Be Bought</title>
      <link>http://seekingalpha.com/article/1304571/comments?source=feed#comment-16995011</link>
      <guid isPermaLink="false">16995011</guid>
      <content>
        <![CDATA[Not sure about beneath the surface, but the heavy amount of investor-owned and ADC CRE lending is certainly something to be a little concerned about (at least to me...)]]>
      </content>
      <pubDate>Fri, 29 Mar 2013 17:02:49 -0400</pubDate>
      <description>
        <![CDATA[Not sure about beneath the surface, but the heavy amount of investor-owned and ADC CRE lending is certainly something to be a little concerned about (at least to me...)]]>
      </description>
    </item>
    <item>
      <title>High Quality And Ample Dry Powder Make Prosperity Bancshares One To Watch</title>
      <link>http://seekingalpha.com/article/1303581/comments?source=feed#comment-16941581</link>
      <guid isPermaLink="false">16941581</guid>
      <content>
        <![CDATA[Jim - <br/>Thanks for spotting that. There are 500+ banks in Texas total, and about 50 with assets between $1B and $4B. I switched the numbers when I was writing and didn't notice that. <br/><br/>As for the number between $100M and $2B, I was talking only about the top 25 MSAs; I believe your 363 number for the state in total. ]]>
      </content>
      <pubDate>Thu, 28 Mar 2013 13:03:00 -0400</pubDate>
      <description>
        <![CDATA[Jim - <br/>Thanks for spotting that. There are 500+ banks in Texas total, and about 50 with assets between $1B and $4B. I switched the numbers when I was writing and didn't notice that. <br/><br/>As for the number between $100M and $2B, I was talking only about the top 25 MSAs; I believe your 363 number for the state in total. ]]>
      </description>
    </item>
    <item>
      <title>High Quality And Ample Dry Powder Make Prosperity Bancshares One To Watch</title>
      <link>http://seekingalpha.com/article/1303581/comments?source=feed#comment-16932101</link>
      <guid isPermaLink="false">16932101</guid>
      <content>
        <![CDATA[Thanks Nick. ]]>
      </content>
      <pubDate>Thu, 28 Mar 2013 10:27:25 -0400</pubDate>
      <description>
        <![CDATA[Thanks Nick. ]]>
      </description>
    </item>
    <item>
      <title>ExactTarget Needs A Decade Of Exceptional Growth To Hit Its Targets</title>
      <link>http://seekingalpha.com/article/1295891/comments?source=feed#comment-16825241</link>
      <guid isPermaLink="false">16825241</guid>
      <content>
        <![CDATA[I was very clear about how I value(d) ET. I spent over 250 words discussing it. ]]>
      </content>
      <pubDate>Tue, 26 Mar 2013 10:58:46 -0400</pubDate>
      <description>
        <![CDATA[I was very clear about how I value(d) ET. I spent over 250 words discussing it. ]]>
      </description>
    </item>
    <item>
      <title>The Forecast For Synchronoss Looks Cloudy, With A Chance Of Outperformance</title>
      <link>http://seekingalpha.com/article/1292631/comments?source=feed#comment-16673181</link>
      <guid isPermaLink="false">16673181</guid>
      <content>
        <![CDATA[Good question. I think a lot of it depends upon how well alternative cloud offerings (like SkyDrive) embrace a platform/OS-neutral approach. ]]>
      </content>
      <pubDate>Fri, 22 Mar 2013 16:10:32 -0400</pubDate>
      <description>
        <![CDATA[Good question. I think a lot of it depends upon how well alternative cloud offerings (like SkyDrive) embrace a platform/OS-neutral approach. ]]>
      </description>
    </item>
  </channel>
</rss>
